Teplizumab (MGA-031) is a Fc receptor non-binding anti-human Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05.
Decreased circulating hCD4 cells in the peripheral blood.
Decreased in the proportion of T cells in the bone marrow and lung.
Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.
[1]. Kevan C Herold, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613.
[2]. Frank Waldron-Lynch, et al. I Analysis of FcR non-binding anti-CD3 mAb in humanized mice identifies novel human gut tropic cells with regulatory function that are found in patients. Sci Transl Med. 2012 Jan 25;4(118):118ra12.
[3]. Brygida Bisikirska, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115(10):2904-13.